Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | MME |
| Gene Name: | MME |
| Protein Full Name: | Neprilysin |
| Alias: | CALLA; CD10; Common acute lymphocytic leukemia antigen; Enkephalinase; EPN; Membrane metallo-endopeptidase; Membrane metallo-endopeptidase (neutral endopeptidase, enkephalinase, CALLA, CD10); NEP; Neutral endopeptidase; Neutral endopeptidase 24.11 |
| Mass (Da): | 85514 |
| Number AA: | 750 |
| UniProt ID: | P08473 |
| Locus ID: | 4311 |
| COSMIC ID: | MME |
| Gene location on chromosome: | 3q25.2 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 19626 |
| Percent of cancer specimens with mutations: | 1.2 |
| Normal role description: | Thermolysin-like specificity, but activity is almost exclusive confined to acting on polypeptides of up to 30 amino acids. Biologically important in the destruction of opioid peptides by cleavage of a Gly-Phe bond. Involved in the degradation of atrial natriuretic factor. Expressed on a wide variety of normal and cancerous cells. Used for diagnostic purposes, not necessarily correlated with pathophysiology. Role in oncogenesis unclear |